Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kotaro Sugimoto

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 8, 2024
[The Molecular Functions of Claudins in Cancer Development and Progression]Kotaro Sugimoto, Hideki Chiba
Tissue Barriers|April 28, 2021
The claudin-transcription factor signaling pathwayKotaro Sugimoto, Hideki Chiba
Pathology International|July 25, 2025
A Novel Tight Junction-Nuclear Receptor Signaling Pathway Regulating Cancer ProgressionKotaro Sugimoto, Hideki Chiba
Circulation Journal : Official Journal of the Japanese Circulation Society|September 19, 2018
Myocardial Rupture Due to Metastasis of Urothelial CarcinomaKotaro Sugimoto, Mizuko Tanaka, Hideki Chiba
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 20, 2020
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenoneHiromi Rakugi, Satoru Yamakawa, Kotaro Sugimoto
Advances in Therapy|January 20, 2023
Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III StudiesSadayoshi Ito, Yasuyuki Okuda, Kotaro Sugimoto
JMA Journal|May 17, 2021
Bacterial Myocarditis in a Patient with CancerRina Yamashita, Mizuko Tanaka, Hideki Chiba, et al.
Advances in Therapy|August 17, 2022
Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive EffectShuichi Ichikawa, Junko Tsutsumi, Kotaro Sugimoto, et al.
Journal of General and Family Medicine|May 6, 2024
Comparison of clinical findings and subjective symptoms in a case of multiple evanescent white dot syndrome (MEWDS): A case report from a patient's perspectiveKotaro Sugimoto, Toshiki Murakami, Akira Ojima, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 4, 2020
Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blockerKiyoshi Arai, Yuka Morikawa, Naoko Ubukata, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 8, 2024
[The Molecular Functions of Claudins in Cancer Development and Progression]Kotaro Sugimoto, Hideki Chiba
Tissue Barriers|April 28, 2021
The claudin-transcription factor signaling pathwayKotaro Sugimoto, Hideki Chiba
Pathology International|July 25, 2025
A Novel Tight Junction-Nuclear Receptor Signaling Pathway Regulating Cancer ProgressionKotaro Sugimoto, Hideki Chiba
Circulation Journal : Official Journal of the Japanese Circulation Society|September 19, 2018
Myocardial Rupture Due to Metastasis of Urothelial CarcinomaKotaro Sugimoto, Mizuko Tanaka, Hideki Chiba
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 20, 2020
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenoneHiromi Rakugi, Satoru Yamakawa, Kotaro Sugimoto
Advances in Therapy|January 20, 2023
Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III StudiesSadayoshi Ito, Yasuyuki Okuda, Kotaro Sugimoto
JMA Journal|May 17, 2021
Bacterial Myocarditis in a Patient with CancerRina Yamashita, Mizuko Tanaka, Hideki Chiba, et al.
Advances in Therapy|August 17, 2022
Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive EffectShuichi Ichikawa, Junko Tsutsumi, Kotaro Sugimoto, et al.
Journal of General and Family Medicine|May 6, 2024
Comparison of clinical findings and subjective symptoms in a case of multiple evanescent white dot syndrome (MEWDS): A case report from a patient's perspectiveKotaro Sugimoto, Toshiki Murakami, Akira Ojima, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 4, 2020
Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blockerKiyoshi Arai, Yuka Morikawa, Naoko Ubukata, et al.
Pageof 7